Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in pediatric advanced MDS or JMML before HSCT
2014-002388-13Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Response rate at Cycle 3 Day 28. Started Oct 2014; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on 2014-002388-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002388-13.